APIs para pesquisa e impurezas

This compound is a research and development impurity standard. It is synthesized in accordance with the pharmacopoeia, and it is an API impurity. It is also used as a metabolite standard for drug development and metabolism studies. This compound has been tested in HPLC standards.

Remdesivir is an antiviral drug. It is an RNA-dependent RNA polymerase inhibitor that has been shown to be effective against a broad range of RNA viruses, including influenza A and B, rhinovirus, respiratory syncytial virus, and parainfluenza virus. Remdesivir impurity 7 (impurity) is a byproduct of the synthesis process of remdesivir. It is a white crystalline solid with a strong chemical odor. This impurity can be synthesized in high purity as well as in custom specifications to meet the needs of pharmaceutical companies developing new drugs.

Trazodone is a psychotropic agent that belongs to the group of antidepressants. Trazodone hydrochloride impurity C is a metabolite of trazodone and can be used as an impurity standard for the drug product in pharmacopoeia. Trazodone hydrochloride impurity C has been found in urine, blood, and saliva after administration of trazodone. It is also found in the plasma of pregnant women who are taking trazodone to treat depression or anxiety during pregnancy.
Trazodone hydrochloride impurity C is synthesized using a custom synthesis with high purity. It has been shown to have a niche market as an analytical reference material for HPLC standards.

Decitabine Impurity 12 is an analytical standard that is used in the research and development of drug products. It is a high purity, HPLC-grade impurity that complies with USP/NF requirements. Decitabine Impurity 12 has been shown to be a metabolite of decitabine, which is an anti-cancer drug used in the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). This impurity has also been shown to have pharmacopoeia value as an impurity standard for drug products.

Colchicine EP Impurity B is a synthetic, impurity standard that is used in research and development for drug product development. It is also used as an analytical reagent. Colchicine EP Impurity B has been shown to be a metabolite of colchicine, which is found in the natural environment. This impurity can be synthesized by reacting 4-hydroxybenzaldehyde with nitroethane and sodium nitrite in the presence of hydrochloric acid. Analytical methods to detect this impurity include HPLC and GC-MS.

9-Oxo azithromycin B is a metabolite of azithromycin. It is an analytical standard for the HPLC analysis of azithromycin and its metabolites. 9-Oxo azithromycin B has been shown to bind to the ribosomes of bacteria, and inhibit protein synthesis. This drug also has antibiotic activity against Mycobacterium avium and Mycobacterium tuberculosis. 9-Oxo azithromycin B can be used in niche research or as an API impurity.br>
br>
br>

Please enquire for more information about (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(2,3-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hy droxyethoxy)-1,2-cyclopentanediol including the price, delivery time and more detailed product information at the technical inquiry form on this page

Rifaximin Impurity 1 is a synthetic impurity standard for Rifaximin. It is a metabolite of rifaximin and is used in research and development to test the purity of drug products. It has a molecular weight of 314.2 g/mol and molecular formula C9H16N4O4S. This product is not manufactured by or for the original equipment manufacturer (OEM).

Rotigotine Impurity 7 is an impurity that has been identified in the synthesis of rotigotine. Rotigotine Impurity 7 is a synthetic compound with a CAS number of 1229620-82-9. It is intended for use as an analytical standard and as a component in the manufacture of rotigotine, which is indicated for the management of Parkinson's disease. This product has not been tested in animals or humans, and it should be handled with care.

Cetirizine is a drug product that is metabolized to cetirizine propanediol ester. This impurity has been identified in the drug and is not expected to cause any adverse effects in humans. Cetirizine propanediol ester can be synthesized and purified through high-purity, analytical, and natural methods. The pharmacopoeia defines cetirizine propanediol ester as a metabolite of cetirizine. It can also be used as an impurity standard for HPLC analysis.

10,11-Dihydroxy-d10 Carbamazepine is a drug product that is used as an analytical reference standard. It is natural and synthetic impurity in the API (active pharmaceutical ingredient) Carbamazepine. The CAS number for 10,11-Dihydroxy-d10 Carbamazepine is 513-81-5. This compound has been synthesized by custom synthesis and is an impurity standard for HPLC analysis of carbamazepine. 10,11-Dihydroxy-d10 Carbamazepine is also a research and development chemical for the drug development industry. It has been classified as a niche chemical due to its high purity and pharmacopoeia grade.

Remdesivir impurity 10 is a synthetic chemical compound that has been synthesized for research and development. It is an impurity standard of remdesivir, which is not present in any drug product. The purity of this product is high, and it can be used as a pharmacopoeia or drug development standard. It can also be used as an analytical standard to measure the concentration of metabolites in animal studies or metabolism studies.

Dapagliflozin Impurity 4 is a research and development impurity standard for the drug Dapagliflozin. Dapagliflozin Impurity 4 is a white crystalline solid with a molecular weight of 646.5 and an empirical formula of C20H22N2O2. It is soluble in water, methanol, ethanol, and acetonitrile. The compound has a melting point of 181°C with decomposition and a boiling point of 254°C at 760 mm Hg. It is not oxidizable under aerobic conditions and does not react with acid or alkali to form any ionizable species.

CPI 0610 is a medicinal compound that acts as a potent inhibitor of protein phosphorylation. It has been shown to inhibit the cell cycle and promote apoptosis in Chinese hamster ovary cells. CPI 0610 is an effective inhibitor of kinase activity in cancer cells, leading to decreased tumor growth and increased survival rates. In preclinical studies, CPI 0610 has demonstrated efficacy against a wide range of cancers, including breast, prostate, and lung cancer. This inhibitor has also been shown to be effective in human cancer cell lines, making it a promising candidate for future cancer therapies.

4-(Phthalazin-1-yloxy)aniline is an analog of cyclin-dependent kinase (CDK) inhibitors that has shown promising anticancer activity. It inhibits the activity of CDKs, which are enzymes involved in regulating cell division and proliferation. This compound has been tested on Chinese hamster ovary cells and has demonstrated potent antiproliferative activity against various cancer cell lines. 4-(Phthalazin-1-yloxy)aniline induces apoptosis in tumor cells, leading to their death. This compound may be a potential candidate for the development of novel anticancer drugs that target CDKs and promote tumor cell death. Additionally, this compound can be detected in urine samples, making it a useful biomarker for cancer diagnosis and monitoring.